• Earlier in July 2026, Voyager Technologies completed its acquisition of Astrobotic, now Voyager Lunar Systems, following new NASA lunar lander task orders worth about US$298 million, while also signing memoranda of understanding with Geisinger and The Pennsylvania State University to expand its Voyager Institute for Space, Technology and Advancement into life sciences, biopharma, in-space manufacturing and defense research.
• Together, these agreements deepen Voyager’s access to NASA-funded lunar missions and broaden its VISTA ecosystem into microgravity-enabled health innovation and national security applications, potentially enriching the pipeline of research, technology and future contract opportunities.
• We’ll now consider how Voyager’s expanded microgravity research partnership with Geisinger interacts with its existing investment narrative built around backlog and space infrastructure.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Voyager Technologies Investment Narrative Recap

To own Voyager Technologies, you have to believe it can turn its NASA and defense exposure, especially Starlab and missile defense, into sustainable, higher margin infrastructure and services. The Astrobotic acquisition and new US$298 million lunar task orders reinforce the near term focus on program execution and cash needs, while VISTA’s health and defense partnerships deepen the opportunity set but do not yet change the core risk around ongoing losses and limited cash runway.

The new Geisinger agreement looks most relevant here, because it ties Voyager’s VISTA infrastructure and Starlab access directly to microgravity biopharma and clinical research. By formalizing joint programs and up to US$1 million in external funding pursuits, it connects the long term Starlab catalyst with nearer term utilization, tenant demand and data rich health applications that could matter as investors watch how quickly Voyager turns backlog, including lunar missions, into revenue and operating leverage.

Yet while the lunar wins and VISTA expansion may look encouraging, investors should still be aware of...

Voyager Technologies' narrative projects $975.5 million revenue and $85.7 million earnings by 2029. This requires 80.0% yearly revenue growth and a $212.8 million earnings increase from -$127.1 million today.

Uncover how Voyager Technologies' forecasts yield a $44.73 fair value, a 70% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts saw Voyager’s outlook very differently, assuming revenue of about US$455 million and only US$40 million of earnings by 2029, which contrasts sharply with more optimistic views on Starlab and backlog conversion and could shift again as the Astrobotic and Geisinger news filters into updated models.

Explore 5 other fair value estimates on Voyager Technologies - why the stock might be worth just $43.45!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Voyager Technologies research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Voyager Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Voyager Technologies' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.